PARP1 and neoplasm: The addition of a STING agonist together with a PARPi in pre-clinical models of breast cancer lacking BRCA1 increased anti-tumour immunity resulting in increased therapeutic efficacy that may also be an approach to overcoming resistance to PARP inhibition [193].